Dupilumab reduces oral corticosteroid (OCS) use and severe exacerbations, and improves FEV1 in OCS-dependent, severe asthma with comorbid chronic rhinosinusitis with and without nasal polyps Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

publication date

  • August 1, 2019